Improvement of Low-Density Microelectronic Array Technology to Characterize 14 Mutations/Single-Nucleotide Polymorphisms from Several Human Genes on a Large Scale (Technical Briefs) Improvement of Low-Density Microelectronic Array Technology to Characterize 14 Mutations/Single-Nucleotide Polymorphisms from Several Human Genes on a Large Scale (Technical Briefs)

Improvement of Low-Density Microelectronic Array Technology to Characterize 14 Mutations/Single-Nucleotide Polymorphisms from Several Human Genes on a Large Scale (Technical Briefs‪)‬

Clinical Chemistry 2004, April, 50, 4

    • $5.99
    • $5.99

Publisher Description

Large-scale human genetic studies require new technologies to genotype several samples with relative ease, high accuracy, and reasonable costs. Among the available approaches, a microelectronic array technology has been developed for DNA hybridization analysis of mutations/ single-nucleotide polymorphisms (SNPs) (1-4). The microelectronic array system (NanoChip[R] Molecular Biology Workstation; Nanogen) produces a defined electric field that allows charged molecules, such as nucleic acids, to be transported to any test site, or pad, on the electronic chip (NanoChip cartridge). Electronic-based molecule addressing can rapidly achieve a high concentration of amplicons on each pad of the cartridge. Control of temperature allows use of an optimal thermal stringency to characterize a SNP/mutation in all 100 pads of a cartridge simultaneously (5, 6). A thin hydrogel permeation layer overlies the pads; the presence of avidin or streptavidin in this layer allows the binding of biotinylated PCR products. Although the technology is attractive, only a few protocols for its use have been published (7-11). We describe the development, optimization, and validation of a high-throughput method for SNPs and mutations analysis that allows performance of 1372 characterizations on each chip.

GENRE
Science & Nature
RELEASED
2004
April 1
LANGUAGE
EN
English
LENGTH
8
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
208.2
KB
Multiplex Assays with Fluorescent Microbead Readout: A Powerful Tool, For Mutation Detection (Editorials) Multiplex Assays with Fluorescent Microbead Readout: A Powerful Tool, For Mutation Detection (Editorials)
2004
Molecular Analysis and Genome Discovery Molecular Analysis and Genome Discovery
2011
PCR Applications (Enhanced Edition) PCR Applications (Enhanced Edition)
1999
MIQE & qPCR MIQE & qPCR
2016
Evaluation of DNA Fragment Sizing and Quantification by the Agilent 2100 Bioanalyzer (Technical Briefs) Evaluation of DNA Fragment Sizing and Quantification by the Agilent 2100 Bioanalyzer (Technical Briefs)
2000
MIQE qPCR & dPCR MIQE qPCR & dPCR
2022
Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial) Doping in Sport: Misuse, Analytical Tests, And Legal Aspects (Editorial)
1997
Vitamin E and Coronary Heart Disease in Tunisians (Nutrition) (Clinical Report) Vitamin E and Coronary Heart Disease in Tunisians (Nutrition) (Clinical Report)
2000
Endothelial Nitric Oxide Synthase Haplotypes Are Associated with Features of Metabolic Syndrome (Endocrinology and Metabolism) (Survey) Endothelial Nitric Oxide Synthase Haplotypes Are Associated with Features of Metabolic Syndrome (Endocrinology and Metabolism) (Survey)
2007
Alanine Aminotransferase As an Independent Predictor of Incident Nonalcoholic Fatty Liver Disease (Letters) (Letter to the Editor) Alanine Aminotransferase As an Independent Predictor of Incident Nonalcoholic Fatty Liver Disease (Letters) (Letter to the Editor)
2007
T-Cell Regulatory Gene CTLA-4 Polymorphism/Haplotype Association with Autoimmune Pancreatitis (Clinical Immunology) T-Cell Regulatory Gene CTLA-4 Polymorphism/Haplotype Association with Autoimmune Pancreatitis (Clinical Immunology)
2007
Percent Free Prostate-Specific Antigen in Assessing the Probability of Prostate Cancer Under Optimal Analytical Conditions (Enzymes and Protein Markers) Percent Free Prostate-Specific Antigen in Assessing the Probability of Prostate Cancer Under Optimal Analytical Conditions (Enzymes and Protein Markers)
1998